An Overview of the Heparin-Induced Thrombocytopenia Syndrome (original) (raw)

Semin Thromb Hemost 2004; 30(3): 273-283
DOI: 10.1055/s-2004-831039

Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

• 1Hematologist and Associate Head, Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, and Professor, Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Further Information

Publication History

Publication Date:
29 July 2004 (online)

Heparin-induced thrombocytopenia (HIT) is caused by heparin-dependent, platelet-activating IgG antibodies that increase thrombin generation in vivo, producing a prothrombotic phenotype. In addition to platelet activation, there is in vitro evidence that activation of endothelium and monocytes occurs, perhaps directly by HIT antibodies, but more likely through activated platelet (or microparticle)-endothelial-leukocyte interactions. Patients with cardiac disease receiving heparin present important diagnostic and therapeutic issues when unexpected thrombocytopenia arises. Concomitant vascular disease burden and intravascular catheter use further increase risk of HIT-associated arterial thrombosis in this patient population. Whether arterial thrombosis simply reflects the “hypercoagulability state” of HIT interacting with diseased or injured arteries, or whether arterial “white clots” reflect additional prothrombotic effects of HIT via endothelial and monocyte activation, remains uncertain. Patients with HIT can also develop deep-vein thrombosis, which can progress to limb loss if coumarin (warfarin) leads to severe protein C depletion (coumarin-induced venous limb gangrene). Therapy for patients strongly suspected to have HIT should focus on inhibiting thrombin (or its generation) pharmacologically. Two direct thrombin inhibitors (lepirudin, argatroban) are approved for treating HIT. When using these agents, coumarin anticoagulation should be delayed pending substantial resolution of thrombocytopenia, before cautiously introducing overlapping coumarin therapy.

KEYWORDS

Heparin-induced thrombocytopenia - thrombin generation - platelet activation - endothelium - monocyte

REFERENCES

• 1 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998; 79 1-7
• 2 Alving B M. How I treat heparin-induced thrombocytopenia and thrombosis. Blood. 2003; 101 31-37
• 3 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003; 121 535-555
• 4 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332 1330-1335
• 5 Warkentin T E, Sheppard J I, Horsewood P, Simpson P J, Moore J C, Kelton J G. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000; 96 1703-1708
• 6 Warkentin T E, Roberts R S, Hirsh J, Kelton J G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003; 163 2518-2524
• 7 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia 3rd ed. New York; Marcel Dekker 2004: 107-148
• 8 Gruel Y, Pouplard C, Nguyen P et al.. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003; 121 786-792
• 9 Liu J C, Lewis B E, Steen L H et al.. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol. 2002; 89 979-981
• 10 Warkentin T E, Elavathil L J, Hayward C PM, Johnston M A, Russett J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997; 127 804-812
• 11 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000; 96 846-851
• 12 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res. 2003; 110 73-82
• 13 Warkentin T E, Hayward C PM, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994; 84 3691-3699
• 14 Warkentin T E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev. 1996; 10 249-258
• 15 Warkentin T E, Sheppard J I. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets. 1999; 10 319-326
• 16 Hughes M, Hayward C PM, Warkentin T E, Horsewood P, Chorneyko K A, Kelton J G. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood. 2000; 96 188-194
• 17 Chong B H, Murray B, Berndt M C, Dunlop L C, Brighton T, Chesterman C N. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994; 83 1535-1541
• 18 Denomme G A. The platelet Fc receptor in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia 2nd ed. New York; Marcel Dekker 2004: 223-250
• 19 Amiral J, Bridey F, Dreyfus M et al.. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992; 68 95-96
• 20 Suh J S, Aster R H, Visentin G P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 1998; 91 916-922
• 21 Ziporen L, Li Z Q, Park K S et al.. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood. 1998; 92 3250-3259
• 22 Li Z Q, Liu W, Park K S et al.. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood. 2002; 99 1230-1236
• 23 Marcum J A, Rosenberg R D. The biochemistry, cell biology, and pathophysiology of anticoagulantly active heparin-like molecules of the vessel wall. In: Lane DA, Lindahl U Heparin: Chemical and Biological Properties, Clinical Applications. Boca Raton, FL; CRC Press 1989: 275-274
• 24 Silver D, Kapsch D N, Tsoi E KM. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage. Ann Surg. 1983; 198 301-306
• 25 Visentin G P, Ford S E, Scott J P, Aster R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994; 93 81-88
• 26 Greinacher A, Pötzsch B, Amiral J, Dummel B, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994; 71 247-251
• 27 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987; 316 581-589
• 28 Herbert J M, Savi P, Jeske W P, Walenga J M. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost. 1998; 80 326-331
• 29 Rosenberg R D, Aird W C. Mechanisms of disease: vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999; 340 1555-1564
• 30 Aird W C. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101 3765-3777
• 31 Gross P L, Aird W C. The endothelium and thrombosis. Semin Thromb Hemost. 2000; 26 463-478
• 32 Sedmak D D, Davis D H, Singh U, van de Winkel J GJ, Anderson C L. Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am J Pathol. 1991; 138 175-181
• 33 Favaloro E J. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol. 1993; 71 571-581
• 34 Gröger M, Sarmay G, Fiebiger E, Wolff K, Petzelbauer P. Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J Immunol. 1996; 156 1549-1556
• 35 Yu Z, Lennon V A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999; 340 227-228
• 36 Warkentin T E. Heparin-induced skin lesions. Br J Haematol. 1996; 92 494-497
• 37 Warkentin T E. Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis. Thromb Haemost. 1997; 77(suppl) 562
• 38 Blank M, Shoenfeld Y, Tavor S et al.. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol. 2002; 14 121-129
• 39 Arepally G M, Mayer I M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001; 98 1252-1254
• 40 Pouplard C, Iochmann S, Renard B et al.. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001; 97 3300-3302
• 41 Fareed J, Walenga J M, Hoppensteadt D A et al.. Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clin Appl Thromb Hemost. 1999; 5(suppl 1) S38-S44
• 42 Fareed J, Walenga J M, Hoppensteadt D A et al.. Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Semin Thromb Hemost. 1999; 25(suppl 1) 37-42
• 43 Khairy M, Lasne D, Brohard-Bohn B, Aiach M, Rendu F, Bachelot-Loza C. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Thromb Haemost. 2001; 85 1090-1096
• 44 Barry O P, Pratico D, Savani R C, FitzGerald G A. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998; 102 136-144
• 45 Barry O P, FitzGerald G A. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost. 1999; 82 794-800
• 46 Weismann R E, Tobin R W. Arterial embolism occurring during systemic heparin therapy. Arch Surg. 1958; 76 219-227
• 47 Kwaan H C, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999; 25(suppl 1) 23-27
• 48 Amiral J, Pouplard C, Vissac A M, Walenga J M, Jeske W, Gruel Y. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol. 2000; 109 336-341
• 49 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001; 135 502-506
• 50 Warkentin T E, Bernstein R A. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med. 2003; 348 1067-1069
• 51 Rice L, Attisha W K, Drexler A, Francis J L. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002; 136 210-215
• 52 Balduini C L, Noris P, Bertolino G, Previtali M. Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infarction. Thromb Haemost. 1993; 69 522-523
• 53 Berkowitz S D, Harrington R A, Rund M M, Tcheng J E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 1997; 95 809-813
• 54 Sane D C, Damaraju L V, Topol E J et al.. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol. 2000; 36 75-83
• 55 Bougie D W, Wilker P R, Wuitschick E D et al.. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002; 100 2071-2076
• 56 Chang J C, Lee D, Gross H M. Acute thrombocytopenia after IV administration of a radiographic contrast medium. AJR Am J Roentgenol. 1989; 152 947-949
• 57 Direct Thrombin Inhibitor Trialists’ Collaborative Group . Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet. 2002; 359 294-302
• 58 Lincoff A M, Bittl J A, Harrington R A et al.. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289 853-863
• 59 Jang I-K, Lewis B E, Matthai W H, Kleiman N S. Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2003; 91(suppl) 68A
• 60 Lewis B, Matthai W H, Cohen M, Moses J W, Hursting M J, Leya F. ARG-216/310/311 Study Investigators . Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002; 57 177-184
• 61 Mahaffey K W, Lewis B E, Wildermann N M et al.. ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003; 15 611-616
• 62 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003; 76 2121-2131
• 63 Warkentin T E. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med. 2002; 126 1415-1423
• 64 Warkentin T E, Heddle N M. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003; 2 148-157
• 65 Hong A P, Cook D J, Sigouin C S, Warkentin T E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003; 101 3049-3051
• 66 Makhoul R G, Greenberg C S, McCann R L. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. J Vasc Surg. 1986; 4 522-528
• 67 Warkentin T E, Aird W C, Rand J. Platelet-endothelial interaction: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am Soc Hematol Edu Program). 2003; 497-519
• 68 Lo G K, Warkentin T E. Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: the “4 T’s. Blood. 2003; 102(suppl 1) 535a
• 69 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101 502-507
• 70 Wallis D E, Workman D L, Lewis B E, Steen L, Pifarre R, Moran J F. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999; 106 629-635
• 71 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103 1838-1843
• 72 Lubenow N, Eichler P, Leitz T, Greinacher A. Meta-analysis of three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. Blood. 2002; 100(suppl 1) 501a-502a
• 73 Smythe M A, Warkentin T E, Stephens J L, Zakalik D, Mattson J C. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol. 2002; 71 50-52
• 74 Srinivasan A F, Rice L, Bartholomew J R et al.. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004; 164 66-70

Theodore E WarkentinM.D.

Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences (General Site)

237 Barton St. E., Hamilton

Ontario L8L 2X2, Canada

Email: twarken@mcmaster.ca